None listed
Conditions
Interventions
Drug : GyeJibokryeong-hwan (Hanpoong Pharm & Food Co., 3.0g, bid, oral administration for 8 weeks)
- Arm 1 (Immediate treatment group) - taking Gyejibokryeong-hwan during 0-8 weeks after enrollment
Sponsors
Korea Institute of Oriental Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Those who have shoulder pain with a Visual Analog Scale (VAS) score of 4 or more 2. Those who have blood-stasis score of 9 or more 3. triglycerides (TG) =150 mg/dL or total cholesterol (TC) =200 mg/dL 4. Those who voluntarily agreed to participate this study 5. Those who willing to cooperate during the study period and who will comply with restrictions
Exclusion criteria
Exclusion criteria: 1. People with mental illness who are difficult to communicate 2. Those who are ill-informed and have difficulty communicating 3. Women who are pregnant 4. Those who are paricipating in other clinical trial 5. Any person deemed unsuitable for participating in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Shoulder pain | — |
Secondary
| Measure | Time frame |
|---|---|
| Triglycerides ;Total cholesterol;Ankle Brachial Pressure Index ;Systolic blood pressure ;Blood-stasis score;High density lipoprotein cholesterol ;Low density lipoprotein cholesterol ;Diastolic blood pressure ;Waist circumference ;Body mass index ;Fasting blood sugar ;Resistin ;Serum amyloid P ;C-reactive protein ;D-dimer ;Oximeter;Adverse events;brachial-ankle pulse wave velocity (baPWV) | — |
Countries
Korea, Republic of
Contacts
Public ContactHo-Yeon Go
Semyung University
Outcome results
None listed